摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2,4-trimethyl-1,2-dihydroquinoline-6-yl acetate | 71043-64-6

中文名称
——
中文别名
——
英文名称
2,2,4-trimethyl-1,2-dihydroquinoline-6-yl acetate
英文别名
6-Acetoxy-1,2-dihydro-2,2,4-trimethylquinolin;1,2-dihydro-2,2,4-trimethylquinolin-6-yl acetate;6-acetoxy-2,2,4-trimethyl-1,2-dihydro-quinoline;(2,2,4-trimethyl-1H-quinolin-6-yl) acetate
2,2,4-trimethyl-1,2-dihydroquinoline-6-yl acetate化学式
CAS
71043-64-6
化学式
C14H17NO2
mdl
MFCD00689688
分子量
231.294
InChiKey
PDPJYLYRJOHRGS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,2,4-trimethyl-1,2-dihydroquinoline-6-yl acetate碘甲烷三乙胺 作用下, 以 甲苯 为溶剂, 以84%的产率得到1-acetyl-1,2-dihydro-1,2,2,4-tetramethylquinolin-6-yl acetate
    参考文献:
    名称:
    Antitrypanosomal Activity of 1,2-Dihydroquinolin-6-ols and Their Ester Derivatives
    摘要:
    The current chemotherapy for second stage human African trypanosomiasis is unsatisfactory. A synthetic optimization study based on the lead antitrypanosomal compound 1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate (TDR20364, 1a) was undertaken in an attempt to discover new trypanocides with potent in vivo activity. While 6-ether derivatives were less active than the lead compound, several N1-substituted derivatives displayed nanomolar IC50 values against T. b. rhodesiense STIB900 in vitro, with selectivity indexes up to > 18000. 1-Benzyl-1, 2-dlhydro-2,2,4-trimethylquinolin-6-yl acetate (10a) displayed an IC50 value of 0.014 mu M against these parasites and a selectivity index or 1700. Intraperitoneal administration of 10a at 50 (mg/kg)/day for 4 days caused a promising prolongation of lifespan in T. b. brucei STIB795-infected mice (> 14 days vs 7.75 days for untreated controls). Reactive oxygen species were produced when T. b. brucei were exposed to 10a in vitro, implicating oxidative stress in the trypanocidal mode of action of these 1,2-dihydroquinoline derivatives.
    DOI:
    10.1021/jm900723w
  • 作为产物:
    参考文献:
    名称:
    Antitrypanosomal Activity of 1,2-Dihydroquinolin-6-ols and Their Ester Derivatives
    摘要:
    The current chemotherapy for second stage human African trypanosomiasis is unsatisfactory. A synthetic optimization study based on the lead antitrypanosomal compound 1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate (TDR20364, 1a) was undertaken in an attempt to discover new trypanocides with potent in vivo activity. While 6-ether derivatives were less active than the lead compound, several N1-substituted derivatives displayed nanomolar IC50 values against T. b. rhodesiense STIB900 in vitro, with selectivity indexes up to > 18000. 1-Benzyl-1, 2-dlhydro-2,2,4-trimethylquinolin-6-yl acetate (10a) displayed an IC50 value of 0.014 mu M against these parasites and a selectivity index or 1700. Intraperitoneal administration of 10a at 50 (mg/kg)/day for 4 days caused a promising prolongation of lifespan in T. b. brucei STIB795-infected mice (> 14 days vs 7.75 days for untreated controls). Reactive oxygen species were produced when T. b. brucei were exposed to 10a in vitro, implicating oxidative stress in the trypanocidal mode of action of these 1,2-dihydroquinoline derivatives.
    DOI:
    10.1021/jm900723w
点击查看最新优质反应信息

文献信息

  • Compounds for treating peripheral; neuropathies and other neurodegenerative; disorders
    申请人:Hoke Ahmet
    公开号:US09527817B2
    公开(公告)日:2016-12-27
    Compounds and methods for treating or preventing a neurodegenerative disease, disorder or condition associated with the overall activity of hsp90 but not with the ATPase activity of hsp90, including peripheral neuropathy, such as peripheral neuropathy caused by chemotherapy or diabetes, disorders 5 of the central nervous system, such as Alzheimer's disease and Parkinsons disease, and motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), in a subject are provided.
    本发明提供了用于治疗或预防与hsp90总体活性相关但与hsp90的ATP酶活性无关的神经退行性疾病、紊乱或病症的化合物和方法,包括周围神经病变,例如由化疗或糖尿病引起的周围神经病变,中枢神经系统的紊乱,例如阿尔茨海默病和帕金森病,以及运动神经元疾病,例如肌萎缩性侧索硬化症(ALS),在受试者中。
  • COMPOUNDS FOR TREATING PERIPHERAL; NEUROPATHIES AND OTHER NEURODEGENERATIVE; DISORDERS
    申请人:Hoke Ahmet
    公开号:US20140303203A1
    公开(公告)日:2014-10-09
    Compounds and methods for treating or preventing a neurodegenerative disease, disorder or condition associated with the overall activity of hsp90 but not with the ATPase activity of hsp90, including peripheral neuropathy, such as peripheral neuropathy caused by chemotherapy or diabetes, disorders 5 of the central nervous system, such as Alzheimer's disease and Parkinsons disease, and motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), in a subject are provided.
  • US9527817B2
    申请人:——
    公开号:US9527817B2
    公开(公告)日:2016-12-27
  • [EN] COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHIES AND OTHER NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE NEUROPATHIES PÉRIPHÉRIQUES ET D'AUTRES TROUBLES NEURODÉGÉNÉRATIFS
    申请人:UNIV JOHNS HOPKINS
    公开号:WO2012177831A2
    公开(公告)日:2012-12-27
    Compounds and methods for treating or preventing a neurodegenerative disease, disorder or condition associated with the overall activity of hsp90 but not with the ATPase activity of hsp90, including peripheral neuropathy, such as peripheral neuropathy caused by chemotherapy or diabetes, disorders 5 of the central nervous system, such as Alzheimer's disease and Parkinsons disease, and motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), in a subject are provided.
  • Antitrypanosomal Activity of 1,2-Dihydroquinolin-6-ols and Their Ester Derivatives
    作者:Jean Fotie、Marcel Kaiser、Dawn A. Delfín、Joshua Manley、Carolyn S. Reid、Jean-Marc Paris、Tanja Wenzler、Louis Maes、Kiran V. Mahasenan、Chenglong Li、Karl A. Werbovetz
    DOI:10.1021/jm900723w
    日期:2010.2.11
    The current chemotherapy for second stage human African trypanosomiasis is unsatisfactory. A synthetic optimization study based on the lead antitrypanosomal compound 1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate (TDR20364, 1a) was undertaken in an attempt to discover new trypanocides with potent in vivo activity. While 6-ether derivatives were less active than the lead compound, several N1-substituted derivatives displayed nanomolar IC50 values against T. b. rhodesiense STIB900 in vitro, with selectivity indexes up to > 18000. 1-Benzyl-1, 2-dlhydro-2,2,4-trimethylquinolin-6-yl acetate (10a) displayed an IC50 value of 0.014 mu M against these parasites and a selectivity index or 1700. Intraperitoneal administration of 10a at 50 (mg/kg)/day for 4 days caused a promising prolongation of lifespan in T. b. brucei STIB795-infected mice (> 14 days vs 7.75 days for untreated controls). Reactive oxygen species were produced when T. b. brucei were exposed to 10a in vitro, implicating oxidative stress in the trypanocidal mode of action of these 1,2-dihydroquinoline derivatives.
查看更多